FMS
Fresenius Medical Care AG & Co. KGaA
There isn't enough reported data to score FMS yet.
FMS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Strong | |
| Stable |
FMS's profitability and cash flow are currently strong, and its balance sheet is stable. There isn't enough data to rate its revenue.
FMS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $38.09 | +76% |
| Fair | 12x | $40.06 | +85% |
| Current | 13x | $21.60 | โ |
| Expensive | 16x | $51.64 | +139% |
Historical ranges are pointers, not guarantees.
FMS's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect FMS's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
FMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.30 | +21% |
| Q4 2025 | $3.73 | +84% |
| Q3 2025 | $2.72 | +8.8% |
| Q2 2025 | $2.49 | +24% |
| Q1 2025 | $2.34 | +28% |
| Q4 2024 | $2.03 | +7.4% |
| Q3 2024 | $2.50 | +46% |
| Q2 2024 | $2.01 | -11% |
FMS's earnings per share have fallen from their peak: $3.30 over the past year, against $5.00 in late 2020.
FMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16B | +195% |
| Q4 2025 | $5.6B | -0.3% |
| Q3 2025 | $5.4B | +2.6% |
| Q2 2025 | $5.3B | +0.5% |
| Q1 2025 | $5.4B | +3.3% |
| Q4 2024 | $5.6B | +1.9% |
| Q3 2024 | $5.3B | -3.6% |
| Q2 2024 | $5.3B | -1.2% |
FMS's revenue has picked up after three years of holding roughly level: $16B last quarter, up 195% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.9% | +1.1 points |
| Q4 2025 | 12% | +6.6 points |
| Q3 2025 | 9.8% | 0 points |
| Q2 2025 | 8.9% | 0 points |
| Q1 2025 | 6.8% | +1.6 points |
| Q4 2024 | 5.1% | -3.5 points |
| Q3 2024 | 9.7% | +3.2 points |
| Q2 2024 | 8.9% | +1.5 points |
FMS's operating margin was 7.9% last quarter, up 1.1 points from the same quarter a year ago.
FMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2020 | $555.7M | +$1B |
| Q2 2020 | $2.3B | +278% |
FMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 3.4x | Elevated |
| Q3 2024 | 1.9x | Healthy |
| Q2 2024 | 2.1x | Moderate |
FMS's net debt is about 1.9 years of its operating earnings (EBITDA), about the same as a year ago.
FMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 39.7 | Neutral |
FMS's weekly RSI is 43 (neutral) and its Stochastic is 40 (neutral).
FMS PE vs Healthcare Sector
| Metric | FMS | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 49% below |
| PE % | 69 | 29 | 40 pts above |
FMS is trading at 13x earnings, a 49% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.3 | 3.1% below |
| 20 week MA | $23.1 | 6.5% below |
| 50 week MA | $23.0 | 6% below |
| 100 week MA | $24.2 | 11% below |
| 200 week MA | $22.6 | 4.3% below |
FMS is in a downtrend: it's below all five of its weekly moving averages, and 4.3% below its 200-week average.
FMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.4 | $41.3 | +10% |
| 2021 | $41.3 | $32.1 | -22% |
| 2022 | $32.1 | $16.0 | -50% |
| 2023 | $16.0 | $20.8 | +30% |
| 2024 | $20.8 | $23.0 | +10% |
| 2025 | $23.0 | $24.1 | +5% |
| 2026 YTD | $24.1 | $21.6 | -10% |
FMS has finished higher in four of the last six years. It's down 10% so far in 2026.